Bank of America Corporation restated their buy rating on shares of Puma Biotechnology Inc (NYSE:PBYI) in a research note released on Monday morning. The brokerage currently has a $135.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $117.00.

Other equities research analysts have also recently issued research reports about the company. J P Morgan Chase & Co reissued a buy rating on shares of Puma Biotechnology in a research note on Tuesday, August 1st. Citigroup Inc. reaffirmed a buy rating and set a $114.00 target price on shares of Puma Biotechnology in a research report on Tuesday, July 18th. Stifel Nicolaus reaffirmed a buy rating and set a $118.00 target price (up previously from $105.00) on shares of Puma Biotechnology in a research report on Tuesday, July 18th. Finally, BidaskClub cut Puma Biotechnology from a strong-buy rating to a buy rating in a research report on Thursday, August 10th. One research analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. Puma Biotechnology currently has an average rating of Buy and an average target price of $124.89.

Puma Biotechnology (NYSE:PBYI) opened at 121.175 on Monday. The firm’s market cap is $4.51 billion. Puma Biotechnology has a 52-week low of $28.35 and a 52-week high of $127.02. The firm’s 50-day moving average price is $103.02 and its 200-day moving average price is $74.94.

Puma Biotechnology (NYSE:PBYI) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.32) by ($0.78). Equities research analysts expect that Puma Biotechnology will post ($8.69) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Puma Biotechnology Inc (PBYI) Given Buy Rating at Bank of America Corporation” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/10/10/puma-biotechnology-inc-pbyi-given-buy-rating-at-bank-of-america-corporation.html.

In other Puma Biotechnology news, SVP Richard Paul Bryce sold 1,998 shares of the business’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $94.48, for a total value of $188,771.04. Following the transaction, the senior vice president now owns 27,246 shares of the company’s stock, valued at $2,574,202.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Alan H. Auerbach sold 13,175 shares of the business’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $94.73, for a total value of $1,248,067.75. Following the completion of the transaction, the insider now directly owns 4,170,623 shares in the company, valued at approximately $395,083,116.79. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 45,173 shares of company stock worth $4,738,189. 22.70% of the stock is owned by insiders.

Hedge funds have recently bought and sold shares of the business. Strs Ohio purchased a new position in Puma Biotechnology in the second quarter worth $122,000. Cubist Systematic Strategies LLC purchased a new position in Puma Biotechnology in the second quarter worth $146,000. Kazazian Asset Management LLC purchased a new position in Puma Biotechnology in the second quarter worth $209,000. Teacher Retirement System of Texas purchased a new position in Puma Biotechnology in the second quarter worth $211,000. Finally, Ameritas Investment Partners Inc. boosted its position in Puma Biotechnology by 5.9% in the second quarter. Ameritas Investment Partners Inc. now owns 2,522 shares of the biopharmaceutical company’s stock worth $220,000 after purchasing an additional 140 shares during the last quarter. 80.98% of the stock is currently owned by institutional investors and hedge funds.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Analyst Recommendations for Puma Biotechnology (NYSE:PBYI)

Receive News & Stock Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related stocks with our FREE daily email newsletter.